← 返回

什么抑制了 NK 细胞在肿瘤中的表现

英文原题:What Inhibits Natural Killers' Performance in Tumour.

查看英文原题

What Inhibits Natural Killers' Performance in Tumour.

PubMed 2022/06/24(内容时间) Int J Mol Sci Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

NK 细胞是固有淋巴细胞,能够根据其激活性和抑制性受体的平衡来裂解肿瘤细胞。越来越多的临床试验显示,基于NK细胞的免疫疗法取得了令人鼓舞的结果。与T细胞不同,NK细胞可以独立于抗原呈递,仅基于其激活和抑制受体来裂解肿瘤细胞。目前正在开发多种改善基于NK细胞疗法的策略,所有这些策略都有一个目标:将平衡转向激活。在这篇综述中,我们讨论了目前对NK细胞裂解肿瘤细胞方式以及所有阻止其细胞毒性潜能的抑制信号的理解。

展开英文摘要原文

Natural killer cells are innate lymphocytes with the ability to lyse tumour cells depending on the balance of their activating and inhibiting receptors. Growing numbers of clinical trials show promising results of NK cell-based immunotherapies. Unlike T cells, NK cells can lyse tumour cells independent of antigen presentation, based simply on their activation and inhibition receptors.

Various strategies to improve NK cell-based therapies are being developed, all with one goal: to shift the balance to activation. In this review, we discuss the current understanding of ways NK cells can lyse tumour cells and all the inhibitory signals stopping their cytotoxic potential.

论文信息

作者
Papak I、Chruściel E、Dziubek K、Kurkowiak M、Urban-Wójciuk Z、Marjański T、Rzyman W、Marek-Trzonkowska N
单位
International Centre for Cancer Vaccine Science, University of Gdansk, Ul. Kładki 24, 80-822 Gdansk, Poland.Poland
文献类型
综述
期刊
International journal of molecular sciences2022 Jun 24
原文标识
PubMed 35806034 · DOI 10.3390/ijms23137030